What is Quviviq (daridorexant)?

What is Quviviq (Daridorexant)?

Quviviq (daridorexant) is a dual orexin receptor antagonist (DORA) approved by the FDA for treating adult insomnia characterized by difficulties with sleep onset and/or sleep maintenance. 1

Mechanism of Action

Daridorexant works by blocking both orexin type 1 and type 2 (OX1 and OX2) receptors, thereby reducing the wake drive rather than increasing sedation 1. This distinguishes it from traditional hypnotics that enhance sedation. The drug was specifically designed with an approximately 8-hour effect duration at the 25 mg dose and a terminal half-life of ~8 hours to minimize next-morning residual effects 2, 3.

Available Formulations

• 25 mg tablets (equivalent to 27 mg daridorexant hydrochloride)
• 50 mg tablets (equivalent to 54 mg daridorexant hydrochloride)
• Film-coated tablets for oral administration 1

Clinical Efficacy

The drug demonstrates dose-dependent efficacy, with both 25 mg and 50 mg doses showing significant improvements:

Objective Sleep Parameters (Polysomnography)

• Wake After Sleep Onset (WASO): Reduced by 18-23 minutes with 25 mg and 29 minutes with 50 mg at 1-3 months 4, 5
• Latency to Persistent Sleep (LPS): Decreased by 28-31 minutes with 25 mg and 31-35 minutes with 50 mg 4
• Total Sleep Time: Increased by approximately 15-50 minutes depending on dose 5

Subjective Improvements

• Subjective total sleep time improved by ~15 minutes 5
• Daytime functioning improved, particularly with the 50 mg dose 6
• The 25 mg dose maintains efficacy in subjective total sleep time at 3 months 7

Efficacy Timeline

The drug shows an "efficacy window" phenomenon: effectiveness begins within 1-2 days, persists at 1 month for both doses, and at 3 months the 25 mg dose remains effective for subjective measures 7. Efficacy was maintained during a 12-month extension trial 6.

Safety Profile

Daridorexant is generally well-tolerated with a favorable safety profile, though it carries specific warnings:

FDA Warnings 1

• Decreased awareness and alertness the morning after use
• CNS depressant effects and daytime impairment
• Worsening of depression/suicidal ideation in patients with depression
• Sleep paralysis and hypnagogic/hypnopompic hallucinations
• Cataplexy-like symptoms (mild, similar to other orexin antagonists)
• Complex sleep behaviors (sleepwalking, sleep-driving, eating while not fully awake)

Common Adverse Events

• Somnolence: 5-8% with daridorexant vs. 3% with placebo 5, 6
• Fatigue: Approximately 2-fold increase vs. placebo 5
• Most adverse events are mild in severity and not dose-dependent 6
• Falls occur at similar or lower frequency compared to placebo 6
• Treatment discontinuation rates similar to placebo 5

Important Safety Considerations

• No clinically significant next-morning residual effects in studies 3
• No evidence of withdrawal symptoms 6
• Minimal accumulation with repeated dosing 3
• The 25 mg dose may be associated with increased risk of adverse events of special interest 7

Prescribing Guidelines

Dosing

• Take one tablet within 30 minutes before bedtime
• Only take when able to stay in bed for at least 7 hours
• Do not exceed prescribed dose 1
• May take longer to work if taken with or immediately after meals 1

Contraindications

• Narcolepsy (absolute contraindication)
• Known allergy to daridorexant or any ingredients 1

Special Populations

Daridorexant appears effective and safe in:

• Elderly patients 6
• Patients with comorbid conditions including neurodegenerative disorders, cognitive impairments, psychiatric conditions, epilepsy, and restless leg syndrome 8
• Patients with untreated mild obstructive sleep apnea (OSA): The 50 mg dose improved all sleep parameters and was well-tolerated in patients with comorbid insomnia and mild OSA (AHI 5-<15 events/hour) 9

Drug Interactions

• Avoid alcohol - increases CNS depressant effects 1
• Avoid other sedating medications unless specifically directed by healthcare provider 1

Controlled Substance Status

Quviviq is a Schedule IV (CIV) federally controlled substance due to potential for abuse or dependence. It must be stored securely and not shared with others 1.

Pregnancy and Lactation

• Pregnancy Registry exists (call 1-833-400-9611) to monitor outcomes in exposed pregnancies 1
• Passes into breast milk - discuss feeding options with healthcare provider 1

Clinical Context

While the 2017 AASM guidelines recommend suvorexant (another orexin receptor antagonist) for sleep maintenance insomnia 10, daridorexant represents a newer generation DORA with a more favorable pharmacokinetic profile designed to minimize residual morning effects. The 2016 ACP guidelines noted that orexin receptor antagonists like suvorexant showed moderate-strength evidence for improving sleep parameters with relatively few serious adverse effects 11.

Key advantage: Unlike benzodiazepines and Z-drugs that carry risks of fractures, falls, and cognitive impairment, daridorexant works by reducing wake drive rather than increasing sedation, potentially offering a safer long-term option for chronic insomnia management.